Comparison · NCT00141102-3926df21
Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With SUs
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With SUs. Trial comparisons, record NCT00141102-3926df21. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00141102-3926df21
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00223 | 0.000955 | 0.00522 | wilson | |
| Risk in group 2 | 0.0049 | 0.00274 | 0.00875 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00266 | -0.00672 | 0.00102 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.456 | 0.159 | 1.31 | log | |
| Odds ratio, group 1 over group 2 | 0.455 | 0.158 | 1.31 | log | |
| Number needed to treat, for one fewer participant with the outcome on Celecoxib than on Oral Diclofenac Plus Omeprazole | 375 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Celecoxib | 200 mg BID plus omeprazole placebo and diclofenac SR placebo | 5 | 2,238 | OG000 |
| Group 2 | Oral Diclofenac Plus Omeprazole | Oral diclofenac SR (75 mg BID) plus omeprazole (20 mg once daily \[QD\]) and celecoxib placebo. | 11 | 2,246 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects With SUs
- Description
Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU.
- Time frame
- 6 month treatment duration
- Population
- ITT.
Source ClinicalTrials.gov
Trial
- Title
- Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis
- NCT number
- NCT00141102
- Phases
- PHASE4
- Conditions
- Osteoarthritis, Arthritis, Rheumatoid
- Interventions
- Celecoxib, Diclofenac + Omeprazole
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Results first posted
- 2010-06-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00141102?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00141102-3926df21